AB Science S.A. (OTCMKTS:ABSCF – Get Free Report) was the recipient of a significant growth in short interest during the month of April. As of April 30th, there was short interest totaling 22,583 shares, a growth of 80,553.6% from the April 15th total of 28 shares. Based on an average daily trading volume, of 1 shares, the days-to-cover ratio is presently 22,583.0 days.
AB Science Stock Performance
OTCMKTS:ABSCF remained flat at $1.12 during trading hours on Monday. The stock has a 50 day moving average price of $1.40 and a two-hundred day moving average price of $1.37. AB Science has a 1-year low of $1.12 and a 1-year high of $1.37.
About AB Science
AB Science is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the discovery and development of protein kinase inhibitors. Its core focus is on the design of orally administered small-molecule therapies that target key signaling pathways involved in oncology, inflammatory disorders and neurodegenerative diseases. The company’s lead asset, masitinib, is a selective tyrosine kinase inhibitor that has been evaluated in multiple Phase 2 and Phase 3 clinical trials, including studies in mastocytosis, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and severe asthma.
Since its founding in 2001 by Dr.
See Also
- Five stocks we like better than AB Science
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for AB Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AB Science and related companies with MarketBeat.com's FREE daily email newsletter.
